4.7 Article

The Animal Lectin Galectin-8 Promotes Cytokine Expression and Metastatic Tumor Growth in Mice

Journal

SCIENTIFIC REPORTS
Volume 10, Issue 1, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-020-64371-z

Keywords

-

Funding

  1. Samuil and Petr Polsky Prostate Cancer Research Fund

Ask authors/readers for more resources

Secreted animal lectins of the galectin family are key players in cancer growth and metastasis. Here we show that galectin-8 (gal-8) induces the expression and secretion of cytokines and chemokines such as SDF-1 and MCP-1 in a number of cell types. This involves gal-8 binding to a uPAR/LRP1/integrin complex that activates JNK and the NFkB pathway. Cytokine and chemokine secretion, induced by gal-8, promotes migration of cancer cells toward cells treated with this lectin. Indeed, immune-competent gal-8 knockout (KO) mice express systemic lower levels of cytokines and chemokines while the opposite is true for gal-8 transgenic animals. Accordingly, gal-8 KO mice experience reduced tumor size and smaller and fewer metastatic lesions when injected with cancer cells. These results suggest the existence of a 'vicious cycle' whereby gal-8 secreted by the tumor microenvironment, promotes secretion of chemoattractants at the metastatic niche that promote further recruitment of tumor cells to that site. This study further implicate gal-8 in control of cancer progression and metastasis through its effects on the production of immunoregulatory cytokines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Organelle Crosstalk in Membrane Dynamics and Cell Signalling

Michael Selitrennik, Sima Lev

BIOCHEMICAL SOCIETY TRANSACTIONS (2016)

Article Oncology

Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis

Nandini Verma, Anna-Katharina Mueller, Charu Kothari, Effrosini Panayotopoulou, Amir Kedan, Michael Selitrennik, Gordon B. Mills, Lan K. Nguyen, Sungyoung Shin, Thomas Karn, Uwe Holtrich, Sima Lev

CANCER RESEARCH (2017)

Article Oncology

Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells

Effrosini G. Panayotopoulou, Anna-Katharina Muller, Melanie Boerries, Hauke Busch, Guohong Hu, Sima Lev

ONCOTARGET (2017)

Article Biochemical Research Methods

Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer

Sung-Young Shin, Anna-Katharina Mueller, Nandini Verma, Sima Lev, Lan K. Nguyen

PLOS COMPUTATIONAL BIOLOGY (2018)

Article Cell Biology

PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein

Amir Kedan, Nandini Verma, Ashish Saroha, Michal Shreberk-Shaked, Anna-Katharina Mueller, Nishanth Ulhas Nair, Sima Lev

CELL DEATH & DISEASE (2018)

Review Cell Biology

Lipid Transfer Proteins and Membrane Contact Sites in Human Cancer

Diego Peretti, SoHui Kim, Roberta Tufi, Sima Lev

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)

Review Biochemistry & Molecular Biology

Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis

Sima Lev

BIOCHEMICAL SOCIETY TRANSACTIONS (2020)

Article Multidisciplinary Sciences

Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis

Nandini Verma, Yaron Vinik, Ashish Saroha, Nishanth Ulhas Nair, Eytan Ruppin, Gordon Mills, Thomas Karn, Vinay Dubey, Lohit Khera, Harsha Raj, Flavio Maina, Sima Lev

SCIENCE ADVANCES (2020)

Article Multidisciplinary Sciences

Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response

Yaron Vinik, Francisco Gabriel Ortega, Gordon B. Mills, Yilling Lu, Menucha Jurkowicz, Sharon Halperin, Mor Aharoni, Mordechai Gutman, Sima Lev

SCIENCE ADVANCES (2020)

Article Chemistry, Multidisciplinary

Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance

Fabienne Lamballe, Fahmida Ahmad, Yaron Vinik, Olivier Castellanet, Fabrice Daian, Anna-Katharina Muller, Ulrike A. Kohler, Anne-Laure Bailly, Emmanuelle Josselin, Remy Castellano, Christelle Cayrou, Emmanuelle Charafe-Jauffret, Gordon B. Mills, Vincent Geli, Jean-Paul Borg, Sima Lev, Flavio Maina

Summary: A unique mouse model of TNBC has been developed, faithfully recapitulating the intertumoral heterogeneity of human TNBC tumors. Targeting both WEE1 and BCL-XL synergistically kills TNBC cells and efficiently induces tumor regression, providing potential therapeutic targets for TNBC treatment.

ADVANCED SCIENCE (2021)

Article Biochemistry & Molecular Biology

Accelerating AXL targeting for TNBC therapy

Lohit Khera, Sima Lev

Summary: AXL, a tyrosine kinase receptor in the TAM family, is a promising therapeutic target for various hematological cancers and solid tumors. It plays a role in multiple protumorigenic processes and targeting AXL alone or in combination with other therapeutic agents could be beneficial, particularly in triple negative breast cancer.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2021)

Article Chemistry, Multidisciplinary

Mouse Modeling Dissecting Macrophage-Breast Cancer Communication Uncovered Roles of PYK2 in Macrophage Recruitment and Breast Tumorigenesis

Anna-Katharina Mueller, Ulrike A. Koehler, Sebastien Trzebanski, Yaron Vinik, Harsha Mohan Raj, Jean-Antoine Girault, Nir Ben-Chetrit, Antonio Maraver, Steffen Jung, Sima Lev

Summary: This study finds that macrophage infiltration in mammary tumors is associated with tumor progression, metastasis, and poor clinical outcome. Ablation of the TYRO3 kinase PYK2 can reduce the number of infiltrating macrophages, inhibit tumor angiogenesis and growth, and modulate monocyte recruitment, macrophage polarization, and tumor angiogenesis. Targeting PYK2 may be an effective strategy to modulate the tumor microenvironment and sensitize breast cancer to immunotherapy.

ADVANCED SCIENCE (2022)

Article Cell Biology

Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors

Nishanth Belugali Nataraj, Ashish Noronha, Joo Sang Lee, Soma Ghosh, Harsha Raj Mohan Raju, Arunachalam Sekar, Binyamin Zuckerman, Moshit Lindzen, Emilio Tarcitano, Swati Srivastava, Michael Selitrennik, Ido Livneh, Diana Drago-Garcia, Oscar Rueda, Carlos Caldas, Sima Lev, Tamar Geiger, Aaron Ciechanover, Igor Ulitsky, Rony Seger, Eytan Ruppin, Yosef Yarden

Summary: By establishing multi-omics pipelines, we discovered that overexpression of NUP93 is associated with aggressive human mammary tumors, enhancing their migration and invasion capabilities. NUP93 is involved in nuclear transport, activating various signaling pathways and ultimately contributing to tumor growth and metastasis. Targeting this nuclear transport process with myristoylated peptides can inhibit tumor growth and metastasis.

CELL REPORTS (2022)

Article Medicine, Research & Experimental

BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators

Olivier Castellanet, Fahmida Ahmad, Yaron Vinik, Gordon B. Mills, Bianca Habermann, Jean-Paul Borg, Sima Lev, Fabienne Lamballe, Flavio Maina

Summary: The study found that high expression levels of BCL-XL and specific cell cycle regulators correlate with poor survival outcomes in TNBC patients. Co-targeting BCL-XL and CDK1/2/4 can inhibit tumor growth, synergistically inhibiting cell viability by combinatorial depletion of survival and RTK/AKT signals, and concomitantly restoring FOXO3a tumor suppression actions.

THERANOSTICS (2021)

No Data Available